Investigational drug · Phase 2
GenSci136
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Patients With MG (gMG and oMG).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "GenSci136"
First trial start
2026
Dec 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GenSci136", any sponsor or status.
Conditions studied
As listed on its trial records.
- Patients With MG (gMG and oMG)
Largest trials
Live from ClinicalTrials.gov: studies naming "GenSci136" as an intervention, largest first.
- Clinical Trial of GenSci136 in Patients With Myasthenia GravisNot yet recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07936084 · 72 participants (planned) · Start Dec 2026 · Primary completion Dec 2028
Drug: GenSci136 for injection · For: Patients With MG (gMG and oMG)
Sites: Shanghai, China
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07366866 · 56 participants (planned) · Start Mar 16, 2026 · Primary completion Feb 7, 2027
Drug: GenSci136; Placebo · For: Autoimmune Disease
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.